TherapeuticsMD (NASDAQ:TXMD) Shares Pass Below Fifty Day Moving Average – Here’s Why

TherapeuticsMD, Inc. (NASDAQ:TXMD) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.05 and traded as low as $2.03. TherapeuticsMD shares last traded at $2.03, with a volume of 14,096 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of TherapeuticsMD in a research note on Thursday, July 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, TherapeuticsMD currently has a consensus rating of “Sell”.

TherapeuticsMD Trading Down 1.5%

The stock has a market capitalization of $23.49 million, a price-to-earnings ratio of 33.83 and a beta of 0.59. The firm has a 50-day moving average of $2.05 and a 200 day moving average of $2.15.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.12) by $6.13. TherapeuticsMD had a net margin of 5.34% and a return on equity of 0.32%. The company had revenue of $0.72 million during the quarter, compared to the consensus estimate of $19.77 million.

Institutional Investors Weigh In On TherapeuticsMD

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TXMD. Citadel Advisors LLC lifted its holdings in TherapeuticsMD by 125.5% in the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock worth $36,000 after buying an additional 19,073 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of TherapeuticsMD by 171.8% during the fourth quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock valued at $157,000 after acquiring an additional 61,000 shares in the last quarter. Finally, Tejara Capital Ltd increased its position in shares of TherapeuticsMD by 1.9% during the fourth quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock worth $572,000 after acquiring an additional 6,649 shares during the last quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.